Does Rallies show 13F holders for MESO?

Yes. Rallies tracks hedge fund and 13F ownership data for MESO, including fund names, share counts, latest tracked quarter, and position changes when available.

Is MESO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MESO. It does not provide personalized investment advice.

MESO (Mesoblast Limited American Depositary Shares) Stock Analysis - Hedge Fund Holdings

Mesoblast Limited American Depositary Shares (MESO) is a publicly traded Healthcare sector company. As of May 21, 2026, MESO trades at $14.52 with a market cap of $1.89B and a P/E ratio of 0.00. MESO moved -0.10% today. Year to date, MESO is -20.61%; over the trailing twelve months it is +25.82%. Its 52-week range spans $7.09 to $22.00. Analyst consensus is buy with an average price target of $35.00. Rallies surfaces MESO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns MESO stock?

Hedge funds tracked by Rallies that own MESO include Oaktree Capital and Polen Capital. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Mesoblast Limited American Depositary Shares.

MESO Key Metrics

Key financial metrics for MESO
Metric	Value
Price	$14.52
Market Cap	$1.89B
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$22.00
52-Week Low	$7.09
Volume	0
Avg Volume	0
Revenue (TTM)	$0
Net Income	$0
Gross Margin	0.00%

Top Hedge Funds Holding MESO

Oaktree Capital holds 179.59K shares of MESO, changed +0.00% as of Dec 31, 2024.
Polen Capital holds 23.00K shares of MESO, changed +0.00% as of Dec 31, 2025.

Latest MESO News

Mesoblast Reports US$30.3M Ryoncil Revenues and Hits Phase 3 Back Pain Trial Target — Apr 30, 2026
Mesoblast Hits 300-Patient Milestone in Phase 3 Low Back Pain Trial — Apr 29, 2026
Mesoblast Secures Worldwide CAR License, Issues ASX Shares to Boost MSC Potency — Apr 15, 2026
Mesoblast Acquires CAR Platform, Ryoncil Nears US$100M Sales and DMD IND — Apr 8, 2026
Mesoblast Secures FDA Clearance for 76-Patient Phase III Ryoncil Trial in DMD — Apr 8, 2026

Recent MESO Insider Trades

George Gregory bought 2.32M (~$3.44M) on Apr 10, 2026.
George Gregory bought 2.32M (~$3.44M) on Apr 10, 2026.
George Gregory bought 886.89K (~$1.27M) on Apr 9, 2026.

MESO Analyst Consensus

2 analysts cover MESO: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $35.00.

Common questions about MESO

Who owns MESO stock?: Hedge funds tracked by Rallies that own MESO include Oaktree Capital and Polen Capital. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Mesoblast Limited American Depositary Shares.
Does Rallies show 13F holders for MESO?: Yes. Rallies tracks hedge fund and 13F ownership data for MESO, including fund names, share counts, latest tracked quarter, and position changes when available.
Is MESO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MESO. It does not provide personalized investment advice.